# Bausch Health Companies Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Bausch Health Companies Inc.).

## Overview

Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company with roots in branded and generic medicines, OTC products, and aesthetics. Its portfolio is organized around five reportable segments: Salix, International, Solta Medical, Diversified, and a controlling stake in Bausch + Lomb. The company focuses on therapeutic areas such as gastroenterology, neurology, dermatology, hepatology, and eye health, with products sold in about 90 countries. A major strategic theme has been simplifying the portfolio and separating non-core assets, most notably the partial spin-off of Bausch + Lomb. The business combines prescription pharmaceuticals, consumer health products, and medical devices, making it exposed to both drug pricing dynamics and device adoption cycles.

## Products & services

• Xifaxan GI prescription product line
• Branded, generic and branded generic pharmaceuticals
• OTC products and dermatology treatments
• Solta Medical aesthetic medical devices
• Bausch + Lomb vision care and surgical products
• Contact lenses and intraocular lenses
• Ophthalmic pharmaceuticals and eye-health devices

- **Gastroenterology pharmaceuticals** (28%) — U.S. GI prescription products sold through the Salix segment, anchored by Xifaxan.
- **Eye health products** (36%) — Bausch + Lomb vision care, surgical, and ophthalmic pharmaceutical products.
- **International pharmaceuticals and OTC** (18%) — Branded, branded generic, and OTC products sold outside the U.S. excluding B+L and Solta.
- **Aesthetic medical devices** (8%) — Solta Medical energy-based aesthetic devices and related consumables.
- **Diversified specialty pharmaceuticals** (10%) — U.S. neurology, dermatology, generic pharmaceuticals, and dentistry products.

- Xifaxan GI prescription product line
- Branded, generic and branded generic pharmaceuticals
- OTC products and dermatology treatments
- Solta Medical aesthetic medical devices
- Bausch + Lomb vision care and surgical products
- Contact lenses and intraocular lenses
- Ophthalmic pharmaceuticals and eye-health devices

## Customers

Bausch Health sells primarily to healthcare professionals and institutions that influence prescribing and purchasing decisions, including physicians, eyecare professionals, hospitals, pharmacies, wholesalers, and large drug store chains. In eye health, repeat usage and low switching behavior matter because contact lens and lens-care customers often stay with familiar brands. The company also relies on government entities and group purchasing organizations, which can affect access and pricing in both pharmaceuticals and devices. For some products, especially dermatology and certain international markets, it uses direct sales, distributors, and cash-pay or fulfillment arrangements to reach patients more efficiently. Customer demand is driven by clinical need, brand trust, reimbursement access, and the ability to maintain formulary or channel placement.

- **Prescribing physicians and specialists** (primary) — Buy or influence use of GI, dermatology, neurology, and ophthalmology products because clinical efficacy and brand familiarity drive repeat prescribing.
- **Eyecare professionals and eye clinics** (primary) — Recommend and purchase contact lenses, lens care, surgical equipment, and ophthalmic pharmaceuticals for recurring patient use.
- **Wholesalers and pharmacy channels** (primary) — Purchase and distribute prescription, OTC, and branded generic products to reach retail and institutional end markets.
- **Hospitals and surgical centers** (secondary) — Buy ophthalmic surgical equipment, intraocular lenses, and selected specialty therapies for procedural use.
- **Government and managed-care buyers** (secondary) — Influence access, reimbursement, and pricing for branded pharmaceuticals through formulary and procurement decisions.

- Physicians who prescribe GI, dermatology, neurology, and ophthalmic products
- Eyecare professionals who recommend lenses, lens care, and surgical products
- Hospitals and clinics that buy surgical, ophthalmic, and specialty therapies
- Pharmacies and wholesalers that distribute prescription and OTC products
- Large drug store chains and distributors that support retail and international reach
- Government entities and group purchasing organizations that influence access and pricing

## Geography

Bausch Health markets products directly or indirectly in approximately 90 countries, making it a globally distributed specialty healthcare business. The U.S. remains the core market for Salix and Diversified, while International covers non-U.S. sales of branded, branded generic, and OTC products. Bausch + Lomb contributes a global eye-health footprint, and the company operates about 37 manufacturing sites worldwide, including 25 Bausch + Lomb facilities. This geographic spread creates exposure to foreign exchange, local regulation, repatriation constraints, and country-specific pricing pressure. The company has also highlighted that foreign operations are subject to political and economic instability, sanctions and anti-bribery compliance, and hard-currency availability in some markets.

- Products are sold in about 90 countries, so the business is globally diversified
- The U.S. is the main market for Salix GI and Diversified specialty pharmaceuticals
- International segment covers non-U.S. branded, branded generic, and OTC sales
- Bausch + Lomb provides a global eye-health platform across many markets
- About 37 manufacturing sites worldwide support supply, quality, and regulatory compliance
- Foreign operations expose the company to FX, repatriation, and local pricing risk

## Strategy

Management is focused on simplifying the portfolio, improving capital structure, and concentrating resources on core businesses where it believes it has sustainable competitive advantages. A central strategic priority is the Bausch + Lomb separation, which is intended to allow each business to allocate capital more effectively and pursue its own growth path. The company is also directing capital toward growth investments, acquisitions, licensing, and infrastructure to support its core franchises. Another priority is improving patient access and affordability, especially for branded prescription products, because access drives volume and long-term franchise durability. These actions are meant to strengthen operating focus while reducing complexity and improving the balance sheet over time.

- **Portfolio simplification and divestitures** (short-term) — Management wants to reduce complexity and concentrate on businesses with sustainable competitive advantage and operational efficiency.
- **Bausch + Lomb separation and post-separation capitalization** (medium-term) — The separation is intended to let each entity focus on its own markets, capital needs, and growth opportunities.
- **Core growth investment** (medium-term) — R&D, licensing, acquisitions, and infrastructure spending are meant to refresh the portfolio and support long-term growth.
- **Patient access and pricing discipline** (short-term) — Access and affordability are critical to sustaining branded prescription volumes and avoiding payer pushback.

- Simplify the portfolio by divesting non-core assets and narrowing focus
- Support the Bausch + Lomb separation to unlock value and sharpen execution
- Improve capital structure through debt management, refinancing, and leverage control
- Invest in core growth drivers through R&D, licensing, and acquisitions
- Expand patient access and affordability to protect branded prescription demand
- Use commercial scale to launch new products and extend existing franchises

## Risks

The company faces significant exposure to generic competition and loss of exclusivity, especially in branded pharmaceutical franchises where a single product can represent a large share of segment revenue. Its high debt load and restrictive covenants create refinancing and liquidity risk, and management explicitly notes the need to generate substantial cash to service obligations. Legal proceedings, investigations, and pricing-related scrutiny can affect both cash flow and commercial flexibility, particularly in a heavily regulated pharmaceutical environment. Because a large portion of revenue comes from international operations, the business is also exposed to foreign exchange volatility, repatriation limits, sanctions, and local political or economic instability. More broadly, healthcare reform, payer pressure, channel concentration, and product quality or regulatory compliance issues can all affect demand, margins, and access to markets.

- **Generic competition and loss of exclusivity** [high] — A large portion of Salix revenue is concentrated in Xifaxan, and the company notes ongoing generic competition and infringement proceedings.
- **Debt servicing and covenant pressure** [high] — The company says it must generate significant cash to service debt and is actively managing its capital structure.
- **Legal proceedings and pricing scrutiny** [high] — Ongoing litigation, investigations, and pricing practice changes can affect revenue, costs, and commercial flexibility.
- **Foreign exchange and international operating risk** [medium] — A substantial share of business is outside the U.S. and Canada, exposing results to currency and local market instability.
- **Regulatory and manufacturing compliance** [medium] — The company operates 37 manufacturing sites and is subject to ongoing inspections and health authority oversight.

- Generic competition and loss of exclusivity can rapidly erode branded drug revenue
- High leverage increases refinancing risk and sensitivity to cash flow volatility
- Legal proceedings and investigations can create cash, reputational, and operational costs
- Pricing pressure from payers, governments, and voluntary access programs can reduce margins
- International operations face FX, repatriation, sanctions, and political risk
- Regulatory and quality compliance failures could disrupt manufacturing or sales
- Channel concentration among wholesalers and large distributors can affect bargaining power

## Accounting

Revenue recognition is a key judgment area because pharmaceutical gross sales are reduced by discounts, rebates, chargebacks, returns, and distribution fees, and the company must estimate these deductions at the time of sale. That means reported net revenue can move differently from shipment volumes when payer mix, channel inventory, or pricing programs change. Goodwill and intangible assets are also highly material because the business has large acquired franchises; goodwill is tested at the reporting-unit level and the company recorded goodwill impairment in its Generics reporting unit in 2025. Intangible amortization is significant and affects operating profit, while the useful lives of finite-lived assets require ongoing reassessment. The company also notes that market conditions and execution risk could trigger future impairment charges, which would materially affect reported earnings without changing cash flow in the period.

- **Revenue deductions and variable consideration** — Can materially change reported sales and margins
- **Goodwill impairment** — Can create large non-cash charges
- **Intangible asset amortization** — Material on EBIT and net income
- **Acquisition-related contingent consideration** — Can introduce earnings volatility

- Net product sales depend on estimates for rebates, returns, chargebacks, and discounts
- Revenue can differ from shipments when channel inventory or pricing changes
- Goodwill impairment testing is important for Dermatology and Generics reporting units
- Finite-lived intangible amortization materially affects operating income
- Acquisition-related contingent consideration and other fair value estimates can move earnings
- Quarterly results may fluctuate with pricing actions, volume changes, and foreign currency

---

*Last updated: 2026-08-11T04:46:23.483540+00:00*